LOGIN
Remimazolam Besylate vs Dexmedetomidine for Sedation in Non-Intubated Geriatric Patients
October 2022
Remimazolam Besylate vs Dexmedetomidine for Sedation in Non-Intubated Geriatric Patients
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1
Efficacy and Safety of Remimazolam Besylate versus Dexmedetomidine for Sedation in Non-Intubated Older Patients with Agitated Delirium After Orthopedic Surgery: A Randomized Controlled Trial
Drug Des Devel Ther. 2022 Aug 1;16:2439-2451. doi: 10.2147/DDDT.S373772. eCollection 2022.. 2022 01-Aug;():. 10.2147/DDDT.S373772Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
Eighty geriatric patients with agitated delirium after orthopaedic surgery were randomized to receive remimazolam besylate (n=40) or dexmedetomidine (n=40) for the resolution of agitation. The primary outcome of interest was the time to resolution of agitation. Secondary outcomes of interest included sedation outcomes, length of stay, and adverse events, as well as vital signs and arterial blood g...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.